Fosfomycin

Fosfomycin is an antibiotic that stands somewhat apart from other antibacterial drugs, both in its chemistry and in the way it works ^[1][2]. Despite the "mycin" ending in its name, it is not a macrolide but a phosphonic acid derivative, a small, simple molecule with the formula C3H7O4P whose most important feature is a strained, chemically reactive three-membered epoxide ring ^[1]. This distinctive structure means there is little cross-resistance between fosfomycin and other antibiotic families, so bacteria resistant to other drugs often remain sensitive to it ^[2]. It is water-soluble, is not bound to blood proteins or broken down by the body, and is excreted largely unchanged through the kidneys into the urine, where it reaches high concentrations ^[2].

The drug was discovered in 1969, originally under the name phosphonomycin, through a collaboration between the American company Merck and the Spanish firm CEPA ^[1]. It was isolated from cultures of Streptomyces soil bacteria by screening for the ability to make bacterial cells swell into fragile spheres, a sign of damage to the cell wall ^[1]. Although it was first obtained from microbes, it is now produced by chemical synthesis ^[1]. It reached the United States market in 1996 and is included on the World Health Organization's List of Essential Medicines ^[1].

Fosfomycin's best-established use is in the treatment of uncomplicated lower urinary tract infections, or cystitis, where its concentration in the urine and its single-dose oral regimen make it a convenient option; taken as the tromethamine salt sold as Monurol, one dose can clear many bladder infections ^[2]. It is active against the common urinary pathogen Escherichia coli, including strains that produce extended-spectrum beta-lactamases and resist many other antibiotics, as well as a range of other gram-negative and gram-positive bacteria ^[1][2]. As resistance to other drugs has spread, interest in fosfomycin has revived, and an intravenous form is used off its original label for more serious problems such as complicated urinary infections, kidney infection, and infections caused by multidrug-resistant organisms, often in combination with other antibiotics ^[3]. A clinical trial found intravenous fosfomycin to be an effective option for complicated upper urinary infections and pyelonephritis ^[3].

Bacteria can become resistant to fosfomycin, either by changing the transporters that carry the drug into the cell or by making enzymes, known as FosA, FosB, and FosX, that break open its reactive ring and inactivate it; the spread of these resistance enzymes among gram-negative bacteria is being watched with concern ^[4]. The drug is generally well tolerated, and its side effects are mostly mild and short-lived, chiefly diarrhoea, nausea, headache, and vaginal yeast infections ^[1][2]. As with many antibiotics, more serious problems such as severe allergic reactions or Clostridioides difficile-associated diarrhoea can occur rarely ^[1]. Its single-dose oral form and favourable safety record have made it a useful choice for treating bladder infection, including during pregnancy ^[2].

Fosfomycin is a prescription antibiotic, usually given as a single sachet for a simple bladder infection. It is generally well tolerated; the usual complaints are diarrhea, nausea, headache, and sometimes vaginitis or dizziness. It is meant for uncomplicated lower urinary tract infections, not for kidney infections or systemic infections where it does not reach high enough levels. Taking it with metoclopramide can lower its absorption, so those are separated. Overall it is considered a reasonable option in pregnancy for cystitis, but as with any antibiotic it should only be used when truly needed.

Fosfomycin has an unusually short interaction list. It is not metabolised by cytochrome P450 enzymes, it is barely protein bound, and it is excreted unchanged in the urine, so the usual metabolic and protein-displacement mechanisms have nothing to act on.

The one documented and clinically real interaction involves gastrointestinal transit. Metoclopramide given with the oral tromethamine sachet lowers both the serum concentration and the urinary excretion of fosfomycin by accelerating passage through the absorptive window, and other drugs that increase gut motility are expected to behave the same way. Because urinary tract infection is treated with a single dose, the consequence is a treatment that quietly fails rather than one that causes harm. Cimetidine was tested for comparison and did not alter fosfomycin pharmacokinetics.

No meaningful interactions have been reported with co-administered antibiotics; fosfomycin's activity in combination is generally additive or synergistic rather than antagonistic.

Checking a whole stack? Run it through interactions + stacks.

Fosfomycin was discovered in 1969 through a collaboration between scientists at Merck Sharp and Dohme and the Spanish company CEPA, who isolated it from cultures of soil-dwelling Streptomyces species; it was originally named phosphonomycin. Chemically it was a striking find, being one of the very few naturally occurring antibiotics built around a phosphonic acid group and bearing a reactive epoxide ring, a structure unlike that of any other antibiotic class.

Its mechanism, blocking the very first committed step in bacterial cell-wall synthesis by inactivating the enzyme MurA, was equally distinctive. For many years it was used chiefly in parts of Europe and Japan, but its most familiar modern form is the single oral dose of fosfomycin tromethamine, sold as Monurol, for uncomplicated bladder infections. An intravenous formulation is used in hospitals against serious and drug-resistant infections, and the drug appears on the World Health Organization's List of Essential Medicines.

Fosfomycin has enjoyed a genuine renaissance in the era of antibiotic resistance, prized because its unusual mechanism and target mean that bacteria resistant to other drug families, including many extended-spectrum beta-lactamase-producing strains of E. coli, often remain susceptible to it. The convenience of a single oral sachet for uncomplicated cystitis is a considerable practical advantage, encouraging adherence and simplifying treatment.

Its long clinical history and its place on the essential-medicines list reinforce confidence in its safety. Honest discussion notes that resistance can develop, that the single-dose oral regimen is best reserved for lower urinary tract infection rather than more serious disease, and that the intravenous form, valuable against multidrug-resistant organisms, has historically been less available in some countries including the United States. As a well tolerated agent that sidesteps common resistance mechanisms, it is increasingly valued.